You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: evidence exists for 33 different treatment options for osteoarthritis of the knee

https://doi.org/10.1136/ebm.9.3.81

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145–55.
    OpenUrlAbstract/FREE Full Text

    
 
 Q What is the evidence for therapeutic interventions used in knee osteoarthritis (OA)?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ Rheumatology ★★★★★☆☆

    METHODS

    Embedded ImageData sources:

    Medline and BIDS EMBASE/Excerpta Medica (1999 to February 2002 for treatments previously investigated and 1966 to February 2002 for all others).

    Embedded ImageStudy selection and assessment:

    systematic reviews, meta analyses, randomised controlled trials (RCTs), non-randomised controlled trials, and observational studies in English or other European languages were included if they assessed a treatment for pain or function, or both, in knee OA. Knee OA had to be supported by clinical and/or radiological evidence. Studies combining knee OA treatment with other types of OA were excluded. Studies were assessed for quality.

    Embedded ImageOutcomes:

    pain, function, and toxicity.

    MAIN RESULTS

    103 intervention trials were identified for the overall analysis that involved 33 interventions including non-pharmacological, pharmacological, intra-articular, and surgical treatments for knee OA. Quality scores …

    View Full Text

    Footnotes

    • For correspondence: Professor M Dougados, Hôpital Cochin, Paris, France. m.dougcch.ap-hop-paris.fr

    • Source of funding: Bristol Myers Squibb.